Nowadays, agents targeting biological processes are being used for metastatic RCC, such as drugs targeting vascular endothelial growth factor, platelet-derived growth factor, and mammalian target of rapamycin [3]. This evidence concerns the gene MTOR and renal cell carcinoma.